Barclays Miami: Ocular Therapeutix's Chair Pravin Dugel discusses feedback he has been receiving on SOL-1 since announcing it last month
Mar 11, 2026
10:45
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
He gives his take on two questions being discussed the most: 1) is AXPAXLI approvable on one study and 2) how might physicians think about using it in practice.
BiotechTV - News